Amalgamated Bank Lowers Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Amalgamated Bank trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 4.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 45,945 shares of the medical research company’s stock after selling 2,367 shares during the quarter. Amalgamated Bank’s holdings in IQVIA were worth $10,631,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. AdvisorNet Financial Inc grew its stake in shares of IQVIA by 327.6% in the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 95 shares during the last quarter. BKM Wealth Management LLC purchased a new position in IQVIA in the 4th quarter valued at $32,000. Activest Wealth Management acquired a new position in IQVIA in the 4th quarter valued at $35,000. CVA Family Office LLC purchased a new position in IQVIA during the 4th quarter worth $43,000. Finally, CoreFirst Bank & Trust purchased a new stake in shares of IQVIA in the third quarter valued at about $44,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. BTIG Research initiated coverage on IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price target on the stock. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Robert W. Baird decreased their target price on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, SVB Leerink assumed coverage on shares of IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price target for the company. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $257.57.

IQVIA Price Performance

Shares of IQVIA stock traded up $1.23 during trading on Friday, hitting $223.37. 1,052,929 shares of the company were exchanged, compared to its average volume of 831,136. The firm has a 50 day moving average price of $244.56 and a 200 day moving average price of $223.84. The stock has a market capitalization of $40.54 billion, a price-to-earnings ratio of 30.52, a P/E/G ratio of 2.15 and a beta of 1.52. The company has a quick ratio of 0.86, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business’s revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the business earned $2.54 earnings per share. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.12 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In related news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. Insiders sold a total of 41,285 shares of company stock worth $10,331,003 over the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.